At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Temozolomide +1 moredrug
Likely dose
Temozolomide 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1-2 Trial of Temozolomide and Hypofractionated Radiotherapy in Treatment of Supratentorial Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating Temozolomide and Stereotactic Radiosurgery (SRS) for Glioblastoma and 2 related conditions. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the FDA-approved chemotherapy drug temozolomide
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2010
First PostedMay 2010
Primary CompletionNov 2016
Study CompletionNov 2020
TodayJul 2026
First PostedMay 11, 2010
Enrollment StartApr 1, 2010
Primary CompletionNov 1, 2016
Study CompletionNov 15, 2020
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 16.1 years ago
Interventions
Temozolomidedrug
75 mg/m²/day oral, administered concurrently with radiotherapy and as adjuvant therapy.
Stereotactic Radiosurgery (SRS)procedure
Standard of care therapeutic radiotherapy administrated at 25, 30, 35, or 40 Gray (Gy)